- About us
- About Vaccines
- Media centre
- EU initiatives
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
17 April 2019
The six undersigned European health industry associations representing small and large companies welcome the Council and the European Parliament agreement on the Horizon Europe legislation, including areas for partnerships and missions, which clearly demonstrates Europe’s commitment to research and innovation.
We welcome the overall structure and ambition of Horizon Europe. Europe has been at the forefront of life science research and a health mission is a palpable signal that it intends to keep on striving for excellence and impact. The challenges identified in the Horizon Europe “Health” cluster, with activities across the whole research and innovation spectrum, are centred on relevance and impact for patients and society. Read more…
6 March 2019 – Brussels, Belgium: Vaccines Europe launched a Manifesto today calling for action of European policy makers to harness the 2017-2019 momentum on vaccination and protect European citizens against vaccine-preventable diseases.
Access the manifesto here.
The manifesto outlines the three visions of the innovative vaccine industry in Europe:
Health for all, highlighting the importance of vaccination throughout the life-span and role of all healthcare professionals in informing their patients about the importance of vaccination as well as being vaccinated themselves;
European excellence, proving the innovative vaccine industry should stay in Europe and what role existing and new vaccines have to play in the fight against AMR; and
Stronger together, summarising the benefits of sustainable vaccine supply and demand ecosystem in Europe and the importance of e-health for national immunisation programmes.
The manifesto highlights the importance of cooperation of all stakeholders in addressing vaccine and vaccination issues in Europe. It lays out the asks of the European-based innovative vaccine industry, a stakeholder who has a role to play in the ongoing EU initiatives on vaccination.
UTRECHT and BILTHOVEN, Netherlands, Feb. 4, 2019 /PRNewswire/ — Recently, the EU-sponsored Vaccines andInfecTious diseases in the Ageing popuLation (VITAL) project was launched. VITAL will address – in a public-private consortium – the challenges of infections in the elderly and the potential of infection prevention by vaccination.
Within the VITAL project, which will run from 2019-2023, University Medical Center (UMC) Utrecht will be the managing entity and scientific lead. The € 12.4 million project is sponsored by the European Union’s Innovative Medicines Initiative(IMI) with a grant of € 5.5 million which will be matched by grants in total of € 6.9 million from the European Federation of Pharmaceutical Industries Associations (EFPIA). The consortium academic leader is prof. dr. Debbie van Baarle, professor of Immunology of Vaccinations at UMC Utrecht and Head of the Department of Immune Mechanisms at the Centre for Immunology of Infectious Diseases and Vaccines at the National Institute of Health and the Environment(RIVM) in the Netherlands.
See the full press release here.
7th December 2018
Vaccines Europe welcomes the EU Council Recommendation on strengthened cooperation against vaccine-preventable diseases. Speaking about the Recommendation, Pascale Mauran, President of Vaccines Europe said “The Recommendation represents a major step towards addressing the different vaccines and vaccination-related challenges faced by the EU Member States such as increasing vaccination hesitancy, low vaccine uptake. Implementing the Recommendation will require stronger collaboration between all relevant stakeholders, in particular, national public health authorities and the European Commission. At Vaccines Europe we are looking forward to collaborating and supporting the implementation of the EU Council Recommendation in order to secure full protection of all EU citizens against vaccine-preventable diseases.”
Vaccination is one of the most powerful and cost-effective public health measures developed in the 20th century and remains the main tool for primary prevention of communicable diseases. Vaccination programs should go beyond childhood, taking a life-course approach to address epidemiological shifts in the burden of vaccine-preventable diseases. Moreover, vaccination can be an important instrument in addressing antimicrobial resistance.
Read the full Vaccines Europe statement here.